Theratechnologies Inc T.TH

Question

[SABBOBCAT]

Wasn't Katana working on peptides to cross the blood bran barrier before selling the platform to TH? Is there any risk that the PDC would cross the BBB and have into tended side effects?

[jfm1330]

You are confusing with Angiochem, another company founded by Dr. Beliveau. Guess who is executive chairman of Angiochem? John Huss, former and short lived CEO of Thera. Small world.

[Lee430]

"He-Who-Must-Not-Be-Named" That was dark times with our former CEO 

[SABBOBCAT]

Okay, great. Thanks for the answer.

[qwerty22]

Sortilin is best known as a brain protein, it's expressed on the surface of neurons. I would think one of the first things you look at is does it cross the BBB. If Katana/thtx haven't ticked this off the to do list early in the process then we are invested in fools. Could they have not done this? Are they all fools?  

[SABBOBCAT]

I have lots of confidence in the medical team, so this is not a dis at them, but it it a bit of a loaded question asking if they are fools LOL. But I guess we are the ones that have bought in, so what does that say about us?

[qwerty22]

What I mean is it's such an obvious question to ask about the tech that they must have done it, they aren't fools, so it must have been asked and answered. Christain said in the KOL event it doesn't cross the BBB, but he just stated it as a fact, he didn't show the expt.

[Wino115]

That was a question in the KOL event and Marsolais emphatically stated their peptide does not cross BBB and Beliveau nodded along with him.    My recollection from reading some of the original Katana and Angiochem material was that the labs initial focus was finding a way to cross the BBB and designing drugs for that purpose.  That is what Angiochem is doing.  same team

[scarlet1967]

"They beat the Gothenburg guys". Below is their patent coverage, the Swedish researchers need to find out how to target the sortilin overexpression not infringing THTX’s with great global coverage and solid patent.   “In another aspect, there is provided a method of treating a cancer involving sortilin expression comprising contacting at least one cancer cell expressing

[qwerty22]

https://www.guventures.com/sortina Sound familiar? I think this is what the mouse lung model is talking to.

[Wino115]

I've tried to keep up on this company but as a private there is little info flow.  Last I could tell they were still in the stage of trying to identify a molecule or molecules that might work as they envision.  It was a press release from some kind of screening company saying they bought one of their machines.  So still super early stages and THTX is way ahead and will likely

[jfm1330]

Kudos must be given to Christian Marsolais here. He is the remaining scientific guy in the company and he had background in cancer before joining Thera. Also, Dr. Beliveau is a mediatic "star" among top scientist in the province of Quebec. So everybody knows him. Also, his former students are a bit everywhere in the bioscience microcosme of the province. I also think that some former lab

[SPCEO1]

I shared Palinc2000's view that Katanna was a lottery ticket when they first bought it. It seemed to me that the chances of a small Montreal-based biotech winning big on an acquistion of an even smaller, pre-clincial Montreal-based biotech that the big boys seemingly had no interest in was not high. So, I enjoyed your explanation of how this deal may have been influenced by other factors as

[jfm1330]

It was much more than a lottery ticket. Lottery ticket means buying anything and relying on total luck for the outcome. With this logic all research related project are lottery tickets, which makes no sense. My guess is that our whiner in chief wants to describe it this way because this acquisition was made under Tanguay. The guy has zero knowledge in science, but he thinks his opinion on this

[jfm1330]

Another message by myself a few days after the acquisition. You can see a quote from the whiner in chief trying to ridicule me for being positive on the acquisition early in the process. Guess who looks like a fool today? Idid not change my view on the science behind the Katana acquisition, and Il loathed the whiner in chief then, and I still do today, and as you can see, for very good reasons

[palinc2000]

Lol!!!T  

[palinc2000]

Hey JMF I think you are close to having a nervous breakdown,,,,,Take your medication,,,,You are the poster who did 180 dedrgrees in the most posts ,,,I dont think I have ever done a 180 and if I had I would have either apologized and or admit I was wrong,,,,something that you have never been man enough to do,Moreover I am not a liar and a coward like you when you throw mud and then pretend to put

[JamesJack]

I would like to send my thank to JFM!  Very clear and useful information offered. SPCEO and Wino, too. Thank you all.

[scarlet1967]

Apart from personal naming and shaming  from both sides I agree with palinc, we are all here to understand our investment based on openions often we make the right analysis and sometimes not. These conversations are not about I said so you said so I am right your wrong etc. To claim that one has been always right or one knows best is not correct or helpful. To me a collective knowledge of all

[palinc2000]

I agree that naming and shaming is not useful but I did not start that and I will retaliate whenever HE does it again. My one and only purpose in being invested in THTX is to make money... and i call shots as I see them from my business background . So when Katana was acquired I was bothered by 3 things 1- Katana had been looking for a partner and or a buyout for more than a year and in spite

[qwerty22]

Katana was a private company right? According to the contract on SEDAR (sept 27 2019) ownership was pretty limited to a couple of LLPs and key employees. Some of them are now employees of thtx or consultants like RB. A lot are names we know. The sale contract stipulates a consultant contract for RB and 3 employment contracts for 3 of the other named sellors. So it isn't the case that the

[scarlet1967]

The first milestone payment will occur when the first patient for the proof of concept trial is enrolled. At that time, approximately US$1,500,000 will be paid through the issuance of common shares of Theratechnologies. "The second milestone will be met when the proof of concept is demonstrated in human subjects, which should be by the end of 2021. This payment will amount to US$1,800,000

[scarlet1967]

"The PK profiles of TH1902 and free docetaxel will be evaluated for all patients in Parts 1 and 2. Once the MTD has been reached in Part 1, patients with TNBC, gynecological cancer (epithelial ovarian or endometrial cancer), colorectal cancer and pancreatic cancer (10 patients per cancer type) will be enrolled in Part 2 and treated at the MTD or RP2D to further assess the safety and

[qwerty22]

I just want to point out you call it a delay, I said I can see them waiting for the full part 1 data set before talking publically. I don't consider that delaying, I think a decision (including the Katana milestone payment) needs to made and the decision should be a fully informed one. I do think if in July say they start talking about shrinking tumours or a good toxicity profile then they

[scarlet1967]

"Pursuant to the terms and conditions of the share purchase agreement dated February 25, 2019, as amended on August 12, 2019, the purchase price, or Purchase Price, for all of the issued and outstanding common shares of Katana was set at CAD 6,900,000 and was payable as to a maximum of CAD 2,600,000 in cash and through the issuance of common shares on the execution date of the agreement, or

[qwerty22]

How do you publically announce an efficacy signal that doesn't impact the future pursuit of the program? Katana guys are meant to sit there and watch the SP increase because the market see the future of the program more certain but at the same time are being told by thtx that nothing has changed? It doesn't add up.  

[scarlet1967]

"The royalties payable under the Transfert Plus License Agreement vary between 1% and 2.5% on net sales of a product based on the licensed technology. If we enter into a sublicense agreement, we must pay amounts varying between 5% and 15% of the revenues received under such sublicense agreement. The percentage varies based on the timing of the execution of such sublicense agreement."

[qwerty22]

So there is a royalty?  

[scarlet1967]

Yep, but it will be quite low and based on NET sales unless they sublicense the drug.

[palinc2000]

Royalty to whom?

[scarlet1967]

7a28e321-0738-438e-9e94-811740e0cfaf 7a28e321-0738-438e-9e94-811740e0cfaf   “Under the Transfert Plus License Agreement, we obtained the exclusive worldwide rights to develop, make, have made, use, sell, offer to sell, distribute, commercialize and import the technology related to the technology platform that uses peptides as a vehicle to deliver existing cytotoxic agents to sortilin

[qwerty22]

Transfert are named as owner of Katana in the sale contract. If I had to guess then some sort of entity set up to handle the royalty payments on behalf of the actual owners. No matter. As consultants, employees, shareholders and royalty receivers they are invested in the future of the program in the short, medium and long term. They haven't taken the loot and left the scene.

[SPCEO1]

Do I understand it correctly that if TH keeps the rights to market TH-1902 themselves they pay significantly less royalties than if the license others to market it? Still, while that incentivizes TH to hold onto as many indications as possible, they almost certainly would still partner on many indications as they likely don't have the capacity to gear up to market all the potential indications

[scarlet1967]

It seems like that, 1 to 2.5% royalty payment of net sales is vey low cost also PDC's are cheap to manufacture so the profit margins are going to be very good if they sublicense the drug the royalties are in low single digits with their worldwide patent coverage one or more deals in different jurisdictions will add nice added revenues. If their technology proven to be successful in treatment

[scarlet1967]

That's their obligation to pay milestones as per the contract.

[qwerty22]

Yes my point if you announce an efficacy signal you are announcing a material change in the program. I can't understand how an efficacy sign isn't central to the future of the program. And the last milestone payment specifically revolves around that. Anyway I'm just trying to manage my own expectations and share my thoughts, no need to resolve this with you.

[palinc2000]

My first reaction upon the acquisition of Katana was based on the public info available then based on the PR announcing the terms of the deal.Please click on the link below https://stockhouse.com/news/press-releases/2019/02/25/theratechnologies-acquires-targeted-oncology-company-katana-biopharma-inc

[palinc2000]

So the selling shareholders will be getting shares of THera representing less than half of one percent of the outstanding shares maybe a little less maybe a little more......Peanuts compared to a royalty of 8% to 15% and even more on the revenue derived from the platform

[qwerty22]

I think we a primarily dealing with individuals here and only 7 of them. The total value was $8.1 mil after an outstanding grant came through and at least 4mil was in stock. I think at an individual level that's a fairly big deal. Remind me how deep the Board is invested? Yes 8% royalty would have been worth much more and would signal a commitment all the way to the end. I still taking half